|
|
Post by brotherm1 on Jul 5, 2016 11:50:54 GMT -5
—The FDA approved Marinol, which is synthetic THC.
That is an interesting point. The FDA and similar regulatory agencies around the world are very concerned about definition of, and delivery of a therapeutic dose. One reason inhaled medications are frowned upon is the variability in the amount of drug delivered to the lung as this can vary widely due to technique by the user. The more potent the dose, the more important precise delivery becomes.
The other matter is potency of the dose. If the active ingredient in a drug is manufactured synthetically (and almost any molecule can be made by a good organic chemist) then the potency is known with a high degree of certainty. Compare that with a plant grown by Farmer Jones in one state with different soil, water, and sunlight compared with that grown by Farmer Smith 1,000 miles away. Both can plant the same seed, but they get very different potencies. Processing plant material to extract specific proteins is a difficult task so pharma companies will wind up using synthetic material just because it is cheaper and easier in the long run.
Perhaps synthetics have a place in the market but their benefits are limited and they appear to have greater side effects. www.hellomd.com/health-wellness/marinol-versus-cannabis-which-is-more-effective |
|
|
|
Post by brotherm1 on Jul 5, 2016 11:55:15 GMT -5
Are you perhaps aware of what exactly GW Pharma is trying to get approved with this phase three? Is it perhaps in the form of pills containing extracts of the plant? Oils? Other? Or are they perhaps testing with inhalable extracts? It's a "child-friendly syrup," according to Reuters (Google Is Your Friend). www.reuters.com/article/us-gw-pharma-cannabis-idUSKCN0WG16ZFrom your GW Pharma/Reuters link, I was unaware GW Pharma had a cannabis type drug already approved in 20 countries and not the US: "Its multiple sclerosis treatment Sativex, which is sprayed under the tongue and is distributed by marketing partners, already has regulatory approval in more than 20 countries, although not the United States." |
|
|
|
Post by peppy on Jul 5, 2016 12:44:26 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 6, 2016 10:07:14 GMT -5
We can offically confirm that at least one former MannKind employee is working with a company developing drug(s) that target cannabinoid receptors. Perhaps some of you will be familiar with this name or have seen it while looking at MannKind patents. • Bryan R. Wilson—Worked for MannKind for over 17 years —Has been involved with numerous MannKind patents —Began working for Cara Therapeutics, Inc in March 2016 • Cara Therapeutics, Inc—"The main naturally occurring ligands for this system, anandamide and 2-arachidonoylglycerol (2-AG), activate a number of cannabinoid receptors, including CB1 and CB2 receptors. Like opioid receptors, CB1 and CB2 receptors are members of the G protein-coupled receptor superfamily. CB1 receptors and associated ligands are mainly localized in the brain whereas CB2 receptors are found mainly in peripheral tissues, particularly immune cells such as leukocytes and mast cells, which have been shown to be involved in pain and inflammatory responses. Cara is developing lead molecules that selectively modulate peripheral CB receptors without targeting CNS cannabinoid receptors. Peripheral CB receptor modulators will be initially developed as a novel therapeutic approach for neuropathic pain, a condition currently without consistently effective therapies. Cara's most advanced CB compound, CR701, is in preclinical development." Website: www.caratherapeutics.com/index.shtml |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 6, 2016 10:23:45 GMT -5
We can offically confirm that at least one former MannKind employee is working with a company developing drug(s) that target cannabinoid receptors. Perhaps some of you will be familiar with this name or have seen it while looking at MannKind patents. • Bryan R. Wilson—Worked for MannKind for over 17 years —Has been involved with numerous MannKind patents —Began working for Cara Therapeutics, Inc in March 2016 • Cara Therapeutics, Inc—"The main naturally occurring ligands for this system, anandamide and 2-arachidonoylglycerol (2-AG), activate a number of cannabinoid receptors, including CB1 and CB2 receptors. Like opioid receptors, CB1 and CB2 receptors are members of the G protein-coupled receptor superfamily. CB1 receptors and associated ligands are mainly localized in the brain whereas CB2 receptors are found mainly in peripheral tissues, particularly immune cells such as leukocytes and mast cells, which have been shown to be involved in pain and inflammatory responses. Cara is developing lead molecules that selectively modulate peripheral CB receptors without targeting CNS cannabinoid receptors. Peripheral CB receptor modulators will be initially developed as a novel therapeutic approach for neuropathic pain, a condition currently without consistently effective therapies. Cara's most advanced CB compound, CR701, is in preclinical development." Website: www.caratherapeutics.com/index.shtmlI have to highlight that many people were downsized in Mannkind corp and your link doesnt mean Mannkind is working with Cara. is Cara's pipeline based on technosphere? If you can confirm that, then they are working together globenewswire.com/news-release/2016/05/31/844932/0/en/Neos-Therapeutics-Appoints-Juergen-Martens-as-Chief-Technology-and-Operations-Officer.html |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 6, 2016 10:31:44 GMT -5
We can offically confirm that at least one former MannKind employee is working with a company developing drug(s) that target cannabinoid receptors. Perhaps some of you will be familiar with this name or have seen it while looking at MannKind patents. • Bryan R. Wilson—Worked for MannKind for over 17 years —Has been involved with numerous MannKind patents —Began working for Cara Therapeutics, Inc in March 2016 • Cara Therapeutics, Inc—"The main naturally occurring ligands for this system, anandamide and 2-arachidonoylglycerol (2-AG), activate a number of cannabinoid receptors, including CB1 and CB2 receptors. Like opioid receptors, CB1 and CB2 receptors are members of the G protein-coupled receptor superfamily. CB1 receptors and associated ligands are mainly localized in the brain whereas CB2 receptors are found mainly in peripheral tissues, particularly immune cells such as leukocytes and mast cells, which have been shown to be involved in pain and inflammatory responses. Cara is developing lead molecules that selectively modulate peripheral CB receptors without targeting CNS cannabinoid receptors. Peripheral CB receptor modulators will be initially developed as a novel therapeutic approach for neuropathic pain, a condition currently without consistently effective therapies. Cara's most advanced CB compound, CR701, is in preclinical development." Website: www.caratherapeutics.com/index.shtmlI have to highlight that many people were downsized in Mannkind corp and your link doesnt mean Mannkind is working with Cara. is Cara's pipeline based on technosphere? If you can confirm that, then they are working together globenewswire.com/news-release/2016/05/31/844932/0/en/Neos-Therapeutics-Appoints-Juergen-Martens-as-Chief-Technology-and-Operations-Officer.htmlWhere did I suggest MannKind was working with Cara? Also, when did MannKind downsize? Wilson left MannKind in 2009. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 6, 2016 10:35:26 GMT -5
Where did I suggest MannKind was working with Cara? Also, when did MannKind downsize? Wilson left MannKind in 2009. Then how is the info you posted relevant? There were atleast 2 rounds of lay off if i recall , in last yr alone |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 6, 2016 10:35:41 GMT -5
Please don't put words in my mouth or spin what I say. I'll make it obvious when I am "assuming" or "speculating" something.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 6, 2016 10:39:10 GMT -5
Where did I suggest MannKind was working with Cara? Also, when did MannKind downsize? Wilson left MannKind in 2009. Then how is the info you posted relevant? There were atleast 2 rounds of lay off if i recall , in last yr alone Where did I suggest MannKind was working with Cara Therapeutics? Lay offs from last year are irrelevant. Bryan Wilson left MannKind in 2009. The information that I shared is relevant because it involves a former employee of MannKind, cannabinoids, a very new company, and this entire thread is full of related topics. Why does what I shared bother you so much? |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 6, 2016 10:48:06 GMT -5
I'll play. What does Rani Therapeutics have to do with MannKind? How are they relevant? What does Google Ventures have to do with MannKind? How are they relevant? Your link doesn't confirm either is working with MannKind. If you can provide evidence that either is using Technosphere then I'll believe it. |
|
|
|
Post by peppy on Jul 7, 2016 0:03:20 GMT -5
We can offically confirm that at least one former MannKind employee is working with a company developing drug(s) that target cannabinoid receptors. Perhaps some of you will be familiar with this name or have seen it while looking at MannKind patents. • Bryan R. Wilson—Worked for MannKind for over 17 years —Has been involved with numerous MannKind patents —Began working for Cara Therapeutics, Inc in March 2016 • Cara Therapeutics, Inc—"The main naturally occurring ligands for this system, anandamide and 2-arachidonoylglycerol (2-AG), activate a number of cannabinoid receptors, including CB1 and CB2 receptors. Like opioid receptors, CB1 and CB2 receptors are members of the G protein-coupled receptor superfamily. CB1 receptors and associated ligands are mainly localized in the brain whereas CB2 receptors are found mainly in peripheral tissues, particularly immune cells such as leukocytes and mast cells, which have been shown to be involved in pain and inflammatory responses. Cara is developing lead molecules that selectively modulate peripheral CB receptors without targeting CNS cannabinoid receptors. Peripheral CB receptor modulators will be initially developed as a novel therapeutic approach for neuropathic pain, a condition currently without consistently effective therapies. Cara's most advanced CB compound, CR701, is in preclinical development." Website: www.caratherapeutics.com/index.shtml Quote: Cara is developing lead molecules that selectively modulate peripheral CB receptors without targeting CNS cannabinoid receptors. Reply: this sounds like a synthetic. Israeli scientists have worked on synthetics. They can make the molecules. They preformed clinical trails. The effects of the synthetics are not as good as the cannabis from what I recall. www.youtube.com/watch?v=c8EdQHWhAT8 CBD definitely blocks the inflammation with clinical score. at 5mg/kg in clinical score."
"if we give less than that we get less action, if we give more than that we get less action."
(At 39 minutes) neuroprotection: "CBG reduces the edema in the brain after injury."
Work done in Israel. screencast.com/t/4zpsWatIJ screencast.com/t/9VIcUj1Ek screencast.com/t/6umatXajCPS
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 7, 2016 17:26:56 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 12, 2016 22:19:25 GMT -5
no opinions on this? this is the only new factual lead
|
|
|
|
Post by mnkdfann on Jul 12, 2016 23:25:28 GMT -5
The reddit site mentioned that the line appears in other sites besides beckyandjoe. It's probably in many others that people just haven't noticed it in yet. My guess is that the people who designed the RLS site probably just cut and pasted parts of someone else's site code. Or some public domain template the line appears in. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 13, 2016 2:02:22 GMT -5
Seriously? We both know you are spreading false information. Look at the proof I have shared. Research for yourself. There is NO other source code that generates a hit in any search. I can confidently say that is NOT a "copied and pasted" source code from "other" people's websites. Provide proof or do not spread flase information. Everything I shared is factual and backed up by proof.
|
|
